MedAbome

MAI002 Clin0 gastric cancer; 5 add'l products RD cancer, autoimmune, sepsis

MedAbome, Inc. is focused on discovering and developing innovative monoclonal antibody (mAb) therapeutics for a variety of diseases, including cancer, infectious diseases, and autoimmune disorders. MedAbome's proprietary live-cell high-throughput screening (LC-HTS) platform identifies innovative antibody drug candidates that target conformational epitopes of novel biomarkers. MedAbome's unique live-cell immunization techniques enable the generation of high-quality monoclonal antibodies. They engineer antibodies to improve their specificity, affinity, and other desired properties. Combining their unique antibody engineering method with their cell-line technique allows them to transfer antibody drug candidates to downstream production processes easily. This technology has led to the generation of dozens of monoclonal antibodies currently in development for a variety of conditions from cancer to autoimmune disease.

Jobs: